Stada Arzneimittel

Stada Arzneimittel AG is a pharmaceutical company based in Bad Vilbel, Germany which specializes in the production of generic and over-the-counter drugs. In 2018, revenue totaled €2.33 billion.

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Hukyndra	Adalimumab	2021-11-15		Juvenile arthritis , Psoriatic arthritis , Psoriasis , Hidradenitis suppurativa , Ulcerative colitis , Ankylosing spondylitis , Rheumatoid arthritis , Uveitis , Crohn disease , Arthritis , Papulosquamous skin diseases
Kinpeygo	Budesonide	2022-07-15	2024-2043	Chronic obstructive pulmonary disease , Asthma , Inflammatory bowel diseases , Allergic rhinitis perennial , Bronchial spasm , Hyperhidrosis , Iga glomerulonephritis , Esophageal diseases , Respiratory tract diseases , Peptic ulcer , Drug-induced abnormalities
Libmyris	Adalimumab	2021-11-12		Juvenile arthritis , Psoriatic arthritis , Psoriasis , Hidradenitis suppurativa , Ulcerative colitis , Ankylosing spondylitis , Rheumatoid arthritis , Uveitis , Crohn disease , Arthritis , Papulosquamous skin diseases
Movymia	Teriparatide	2017-01-11	2025	Osteoporosis, Postmenopausal osteoporosis
Oyavas	Bevacizumab	2021-03-26		Renal cell carcinoma, Colorectal neoplasms, Breast neoplasms, Ovarian neoplasms, Non-small-cell lung carcinoma, Glioblastoma, Fallopian tube neoplasms, Kidney neoplasms, Uterine cervical neoplasms, Peritoneal neoplasms
Silapo	Epoetin zeta	2007-12-18		Chronic kidney failure, Neoplasms, Autologous blood transfusion, Anemia
Ximluci	Ranibizumab	2022-11-09		Diabetes complications, Macular edema, Retinal vein occlusion, Diabetic retinopathy, Wet macular degeneration, Choroidal neovascularization, Degenerative myopia

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication